Isracann Biosciences Stock Current Ratio
Isracann Biosciences fundamentals help investors to digest information that contributes to Isracann Biosciences' financial success or failures. It also enables traders to predict the movement of Isracann Pink Sheet. The fundamental analysis module provides a way to measure Isracann Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Isracann Biosciences pink sheet.
Isracann |
Isracann Biosciences Company Current Ratio Analysis
Isracann Biosciences' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Isracann Biosciences Current Ratio | 0.76 X |
Most of Isracann Biosciences' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Isracann Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Isracann Biosciences has a Current Ratio of 0.76 times. This is 73.88% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current ratio for all United States stocks is 64.81% higher than that of the company.
Isracann Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Isracann Biosciences' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Isracann Biosciences could also be used in its relative valuation, which is a method of valuing Isracann Biosciences by comparing valuation metrics of similar companies.Isracann Biosciences is currently under evaluation in current ratio category among its peers.
Isracann Fundamentals
| Return On Equity | -2.53 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | 2.16 M | |||
| Shares Outstanding | 175.99 M | |||
| Shares Owned By Insiders | 0.50 % | |||
| Price To Book | 9.57 X | |||
| Price To Sales | 8.83 X | |||
| EBITDA | (4.64 M) | |||
| Net Income | (4.69 M) | |||
| Cash And Equivalents | 310.61 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 0.76 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (1.75 M) | |||
| Earnings Per Share | (0.13) X | |||
| Beta | 0.12 | |||
| Market Capitalization | 2.45 M | |||
| Total Asset | 4.09 M | |||
| Z Score | -3.3 | |||
| Net Asset | 4.09 M |
About Isracann Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Isracann Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Isracann Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Isracann Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Isracann Pink Sheet
Isracann Biosciences financial ratios help investors to determine whether Isracann Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isracann with respect to the benefits of owning Isracann Biosciences security.